Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA
www_slon_pics / Pixabay

Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

According to a story from finanznachrichten.de, the Swedish drug company Calliditas Therapeutics has recently announced that the US Food and Drug Administration (FDA) has given one of the company's experimental drugs…

Continue Reading Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

Potential Gene Therapy for Late Infantile Batten Disease Earns Rare Pediatric Disease Designation

According to a story from BioSpace, the biotechnology company REGENXBIO, Inc. recently announced that its experimental gene therapy candidate called RGX-181 has been granted Rare Pediatric Disease designation from the…

Continue Reading Potential Gene Therapy for Late Infantile Batten Disease Earns Rare Pediatric Disease Designation

Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia

A recent study, called TOPCAT, evaluated the effects of spironolactone as a treatment for individuals living with Chronic Kidney Disease (CKD) who are also diagnosed with heart failure with preserved ejection fraction,…

Continue Reading Study Shows Treatment may be Effective for Chronic Kidney Disease but Increase Risk of Hyperkalemia
Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome
source: pixabay.com

Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome (FCS) Is a rare disease caused by malfunctioning lipoprotein lipase. This results in a buildup of triglycerides in the body's plasma. FCS can cause pancreatitis, memory loss, nerve…

Continue Reading Importance of Patient-Centered Research in Familial Chylomicronemia Syndrome
Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial
DarkoStojanovic / Pixabay

Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial

According to a story from labiotech.eu, the biotechnology company Orphazyme has been developing an experimental therapy for Niemann-Pick disease type C. In a recent Phase 2/3 clinical trial, the investigational…

Continue Reading Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial

New Phase 1 Clinical Trial for Potential Oral Medication for Non-Tuberculous Mycobacterial (NTM) Infections

Non-tuberculous mycobacterial (NTM) infections are caused by bacteria found in the environment. In healthy individuals, these bacteria normally cause no harm. However, for those who have a compromised immune system or who…

Continue Reading New Phase 1 Clinical Trial for Potential Oral Medication for Non-Tuberculous Mycobacterial (NTM) Infections

Don’t Miss The Final Screening of “Take A Look At This Heart,” About Love and Intimacy in the Disabled Community

A rarely addressed subject that comes up in discussions about people with disabilities is the subject of romantic relationships, intimacy, and parenting. More than likely, a lot of day to…

Continue Reading Don’t Miss The Final Screening of “Take A Look At This Heart,” About Love and Intimacy in the Disabled Community